BofA raised the firm’s price target on Cytokinetics (CYTK) to $66 from $65 and keeps a Neutral rating on the shares. Given the level of pre-announcements, upcoming Q4 earnings “may not have the same impact they’ve had in prior years,” the analyst tells investors in a preview for the firm’s biopharma coverage.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics assumed with an Overweight at Barclays
- Cytokinetics, Olympic Medalist McLaughlin-Levrone team up for awareness for HCM
- Cytokinetics announces Myqorzo available in U.S.
- Cytokinetics price target raised to $108 from $90 at B. Riley
- 3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts